June 2012 · Vol. 26, No. 06Global Endometrial Ablation for Menorrhagia: The Office Option
Continue to article
Download the CME test
|
The Omnia CME Journal™
Global Endometrial Ablation for Menorrhagia: The Office Option
AUTHOR
Chris Canali, Medical Writer
REVIEWER
Robert L. Barbieri, MD
Chief, Department of Obstetrics and Gynecology
Brigham and Women’s Hospital
Kate Macy Ladd Professor of Obstetrics, Gynecology, and Reproductive Biology
Harvard Medical School
Boston, MA
LEARNING OBJECTIVES
After completing this monograph, the participant should be better able to:
-
Compare and contrast the risks versus benefits of current procedures used for endometrial ablation.
-
Differentiate various methods used for endometrial ablation, and their clinical outcomes, to make the most appropriate selection for the patient.
-
Evaluate current procedures used for endometrial ablation from the perspective of their suitability as in-office procedures.
-
Discuss pain management strategies in reference to endometrial ablation procedures, and implement those strategies to improve patient outcomes.
COURSE DESCRIPTION
In the United States, an estimated 10 millionnew cases of menorrhagia are reported annually, resulting in an overall prevalence of approximately 20%, and a substantial personal burden of disease. Global Endometrial Ablation (GEA) represents a minimally-invasive approach to treating menorrhagia.
Join us in this CME activity, which will: (1) examine the current procedures used for endometrial ablation; (2) compare and contrast methods used for endometrial ablation, including the clinical outcomes; (3) evaluate the suitability of current endometrial ablation treatments as in-office procedures; and (4) examine strategies for pain management with endometrial ablation procedures.
|
Release Date: May 1, 2012 Expiration Date: May 1, 2013  Instructions for Credit
Read the article and complete the post-test and activity evaluation on page S8. Complete online or fax/mail the completed form as indicated on the form instructions. Your test will be graded. If you receive a passing score a certificate will be sent via email. If you do not receive a passing score, you will be contacted via email and given the opportunity to retake the test. Target AudienceThis course is designed to meet the Continuing Medical Education needs of the practicing Obstetrician and Gynecologist, Family Physician, Internist, Nurse Practitioner, and Physician Assistant. Accreditation
The Omnia-Prova Education Collaborative, Inc. (TOPEC) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Credit DesignationThe Omnia-Prova Education Collaborative, Inc. designates this enduring material for a maximum of .75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Acknowledgment of Commercial SupportThis activity is supported by an independent educational grant from CooperSurgical, Inc. Disclosure of Conflicts of InterestTOPEC and Omnia Education assess conflict of interest with its faculty, planners, authors, and reviewers of CME activities. If conflicts of interest are identified for anyone who is in a position to control content, the conflicts are thoroughly vetted and resolved in part by the use of independent reviewers who review content for fair balance, scientific objectivity of studies utilized in the activity, and patient care recommendations. TOPEC and Omnia Education are committed to providing its learners with high quality, unbiased, and state-of-the-art education. FacultyChris Canali has nothing to disclose. Educational Advisory Panel on Global Endometrial AblationLee Philip Shulman, MD, FACOG, FACMG, has disclosed that he is on the speakers’ bureau for, is a consultant for, and has received research grants from Bayer, and is on the speakers’ bureaus and is a consultant for Sequanome, Inc. and Teva. He is on the speakers’ bureaus for GlaxoSmithKline, and Merck, and is a consultant for Genzyme Corporation.
Stephen M. Cohen, MD, FACOG, has disclosed that he is on the speakers’ bureau for Bayer and is on the advisory board for Boston Scientific.
Steven R. Goldstein, MD, has disclosed that he is the director of Sonosite, Inc., on the speakers’ bureaus for Amgen and Warner Chilcott, is a consultant for Cook ObGyn and Philips Ultrasound, and is on the advisory boards for Bayer, Novo Nordisk, Pfizer, and Shionogi.
Keith Isaacson, MD, has disclosed that he is a consultant for Karl Storz Endoscopy.
Robert Rubino, MD, FACOG, has disclosed that he is a consultant for Cooper Surgical and is a principle investigator for Hologic and Interlace Medical.
Robert Zurawin, MD, has disclosed that he is on the speakers’ bureau and is a consultant for Ethicon Women’s Health, is a consultant and on the advisory board for Conceptus, Inc., and is a consultant for Ethicon EndoSurgery. ReviewerRobert L. Barbieri, MD, has nothing to disclose. PlannersBarry A. Fiedel, PhD, has nothing to disclose.
Sean T. Saunders, CCMEP, has nothing to disclose.
Erica Spengler has nothing to disclose.
Susan Specht, RN, MS, COHN, has nothing to disclose. DisclaimerThe views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of The Omnia-Prova Education Collaborative or Omnia Education. This article is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
OBG Management ©2012 Quadrant HealthCom Inc.
|
